Pegylated Interferon for treating covid, after promising interim results from Phase III clinical trials.The drug once approved can be a fresh arsenal in company’s covid portfolio, along with its Remdesivir.
The company had earlier benefitted from Hydroxychloroquine (HCQ), which was indicated for emergency use in covid treatment. With one of the largest manufacturing capacities for HCQ in India, Cadila was a key beneficiary, along with IPCA Ltd.In addition, the company is developing a indigenous vaccine for covid-19, and the Street is awaiting news around that.
The vaccine approval can drive significant re-rating for Cadila, say analysts.Analysts at Motilal Oswal Financial Services see the vaccine opportunity as a potential medium-term.